We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Pramiracetam
A racetam-class nootropic structurally related to piracetam, promoted for memory and focus. Honest appraisal: the human evidence is very thin — essentially a couple of small, decades-old studies (one positive in head-injury patients, one largely unconvincing in Alzheimer's) plus a lot of anecdote. No modern, well-powered trials in healthy people.
What the evidence says
Most Pramiracetam studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 1985–1994 with a typical study size of 10 participants.
Based on 5 studies · 4 RCTs · 10 total participants
Confidence
Moderate confidenceBy outcome
Scores Emerging (2.5) because human evidence is limited to two small, decades-old trials and a review, with no modern controlled data in healthy adults.
Pramiracetam is a member of the racetam family (relatives of piracetam) marketed as a cognitive enhancer for memory and concentration.
Its proposed mechanism is poorly defined: like other racetams it lacks affinity for classical neurotransmitter receptors, and effects are attributed vaguely to enhanced hippocampal high-affinity choline uptake and potentiation of existing neurotransmission rather than any single well-characterized target.
The honest evidence picture is weak. The most-cited human result is a small 1991 double-blind placebo-controlled study in young men with memory deficits after head injury/anoxia, which reported clinically significant improvement in delayed recall.
A 1991 enrichment-design trial in 10 Alzheimer's patients was largely unconvincing — only 2 of 8 'best-dose' responders replicated, and the authors concluded benefit in Alzheimer's was unlikely.
Beyond these and a few comparative reviews, there is essentially no modern, adequately-powered randomized evidence — particularly none in healthy adults seeking cognitive enhancement. Most popular claims are anecdotal. The overall evidence is therefore low/emerging.
Increases sodium-dependent high-affinity choline uptake in rat hippocampal synaptosomes (animal/in-vitro); proposed to indirectly support cholinergic/memory function in humans.
Like other racetams, thought to modulate ion flux and potentiate already-present neurotransmission rather than bind a specific receptor.
How Pramiracetam works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Use caution — racetams are renally cleared.
Use caution due to theoretical platelet effects.
Not studied — avoid.
Racetams have been associated with effects on platelet aggregation; theoretical additive bleeding risk — use caution.
Racetams' cholinergic-leaning activity could be additive with cholinesterase inhibitors or other cholinergics.
Tip: Add a choline source (e.g. citicoline/alpha-GPC); reduce dose
Tip: Lower dose; dose earlier in the day
Tip: Avoid late-day dosing
Tip: Take with food
The current evidence for Pramiracetam is insufficient to assign an evidence score, based on 5 indexed studies. A racetam-class nootropic structurally related to piracetam, promoted for memory and focus. Honest appraisal: the human evidence is very thin — essentially a couple of small, decades-old studies (one positive in head-injury patients, one largely unconvincing in Alzheimer's) plus a lot of anecdote. No modern, well-powered trials in healthy people. Representative study: PMID 1786500.
The commonly studied dose of Pramiracetam is Commonly 400-1200mg/day in divided doses (no robustly validated regimen). Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Pramiracetam is in the morning. Take it with food. Often taken in two or three divided doses earlier in the day; the head-injury trial used 400 mg three times daily.
Pramiracetam is generally safe at recommended doses, with a few precautions worth noting. The most commonly reported side effects are headache, nervousness / agitation, insomnia. Use caution if any of these apply to you: Pregnancy/breastfeeding (not studied); Severe kidney impairment (renal clearance); Known hypersensitivity to racetams.
Alpha-GPC
Likely helpsCrosses the blood-brain barrier to fuel acetylcholine synthesis — supports focus, memory, and power output in athletes.
Citicoline
Probably helpsDual precursor to acetylcholine and phosphatidylcholine — enhances memory, focus, and brain cell membrane repair.
Huperzine A
Likely helpsAcetylcholinesterase inhibitor from club moss, studied mainly for Alzheimer's and dementia; cognitive evidence is mixed and limited by trial quality.
Phosphatidylserine
Mostly mechanism / observationalKey brain membrane phospholipid that facilitates neurotransmitter release, memory formation, and post-exercise cortisol reduction.
Explore: Best supplements for Focus, Memory & Mood
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 5 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research